美国食品药品监督管理局（FDA）已向TRAWS PHARMA公司表明，其计划在3月16日之前，就相关事宜正式传达其监管关切。此次沟通将不仅明确指出FDA所关注的问题，还将附带一系列建议的缓解步骤，旨在为该公司提供明确的指引路径。
美国食品药品监督管理局（FDA）已向TRAWS PHARMA公司表明，其计划在3月16日之前，就相关事宜正式传达其监管关切。此次沟通将不仅明确指出FDA所关注的问题，还将附带一系列建议的缓解步骤，旨在为该公司提供明确的指引路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.